
The latest development from Johnson and Johnson has been met with a wide array of views and opinions from Wall Street analysts of which most are cautiously positive.
Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Johnson & Johnson is an American multinational corporation founded in 1886 that develops medical devices, pharmaceutical and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 37 on the 2018 Fortune 500 list of the largest United States corporations by total revenue. J&J is one of the world’s most valuable companies.
Johnson & Johnson is headquartered in New Brunswick, New Jersey, the consumer division being located in Skillman, New Jersey. The corporation includes some 250 subsidiary companies with operations in 60 countries and products sold in over 175 countries. Johnson & Johnson had worldwide sales of $70.1 billion during calendar year 2015. Johnson & Johnson’s brands include numerous household names of medications and first aid supplies. Among its well-known consumer products are the Band-Aid Brand line of bandages, Tylenol medications, Johnson’s Baby products, Neutrogena skin and beauty products, Clean & Clear facial wash and Acuvue contact lenses.
The latest development from Johnson and Johnson has been met with a wide array of views and opinions from Wall Street analysts of which most are cautiously positive.
Pfizer requires the government to give them access to about nine specialized products which is said to include Lipids, and this can be done by invoking the defense production act.
Pfizer in collaboration with BioNTech is the only COVID-19 developer whose vaccine has already secured an Emergency Use Authorization in the United Kingdom.